CL2023000194A1 - Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo - Google Patents
Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-iloInfo
- Publication number
- CL2023000194A1 CL2023000194A1 CL2023000194A CL2023000194A CL2023000194A1 CL 2023000194 A1 CL2023000194 A1 CL 2023000194A1 CL 2023000194 A CL2023000194 A CL 2023000194A CL 2023000194 A CL2023000194 A CL 2023000194A CL 2023000194 A1 CL2023000194 A1 CL 2023000194A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- oxadiazol
- formulation
- methyl
- low dose
- Prior art date
Links
- -1 5-methyl-1,2,4-oxadiazol-3-yl compound Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000194A1 true CL2023000194A1 (es) | 2023-07-21 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000194A CL2023000194A1 (es) | 2020-07-23 | 2023-01-19 | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230338349A1 (https=) |
| EP (1) | EP4185291B1 (https=) |
| JP (1) | JP2023535034A (https=) |
| KR (1) | KR20230043905A (https=) |
| CN (1) | CN116323604A (https=) |
| AR (1) | AR123031A1 (https=) |
| AU (1) | AU2021312894B2 (https=) |
| BR (1) | BR112023000975A2 (https=) |
| CA (1) | CA3186808A1 (https=) |
| CL (1) | CL2023000194A1 (https=) |
| CO (1) | CO2023000594A2 (https=) |
| DO (1) | DOP2023000009A (https=) |
| EC (1) | ECSP23005057A (https=) |
| ES (1) | ES3039536T3 (https=) |
| IL (1) | IL300023A (https=) |
| JO (1) | JOP20230018A1 (https=) |
| MX (1) | MX2023000993A (https=) |
| PE (1) | PE20231031A1 (https=) |
| PH (1) | PH12023550177A1 (https=) |
| TW (1) | TW202220650A (https=) |
| WO (1) | WO2022020663A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014331A1 (zh) * | 2016-07-22 | 2018-01-25 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| CA3107788A1 (en) * | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4185291B1 (en) | 2025-07-09 |
| AU2021312894B2 (en) | 2025-09-11 |
| WO2022020663A1 (en) | 2022-01-27 |
| MX2023000993A (es) | 2023-03-01 |
| CO2023000594A2 (es) | 2023-01-26 |
| PE20231031A1 (es) | 2023-07-10 |
| CN116323604A (zh) | 2023-06-23 |
| ECSP23005057A (es) | 2023-02-28 |
| JP2023535034A (ja) | 2023-08-15 |
| EP4185291A1 (en) | 2023-05-31 |
| CA3186808A1 (en) | 2022-01-27 |
| IL300023A (en) | 2023-03-01 |
| TW202220650A (zh) | 2022-06-01 |
| AR123031A1 (es) | 2022-10-26 |
| KR20230043905A (ko) | 2023-03-31 |
| EP4185291C0 (en) | 2025-07-09 |
| BR112023000975A2 (pt) | 2023-02-07 |
| DOP2023000009A (es) | 2023-02-15 |
| JOP20230018A1 (ar) | 2023-01-23 |
| PH12023550177A1 (en) | 2024-03-18 |
| US20230338349A1 (en) | 2023-10-26 |
| ES3039536T3 (en) | 2025-10-22 |
| AU2021312894A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| MX2020007633A (es) | Péptidos macrocíclicos contra acinetobacter baumannii. | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| MX2023005462A (es) | Compuestos macrociclicos y metodos para usarlos. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PE20241327A1 (es) | Tratamiento de trastornos hepaticos con un agonista del thr-beta | |
| MX2022005503A (es) | Composiciones farmaceuticas de apixaban de desintegracion oral. | |
| CL2023000194A1 (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo | |
| ECSP23017158A (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| AR129937A1 (es) | Derivados de 1,3,4-oxadiazol como inhibidores selectivos de histona desacetilasa 6 | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CO2025010159A2 (es) | Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo | |
| AR132497A1 (es) | Combinación de obicetrapib amorfo e inhibidor de sglt2 | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| DOP2024000018A (es) | Antagonistas del receptor muscarínico 4 y métodos de uso | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| UY39649A (es) | Compuesto para el tratamiento de trastornos cognitivos | |
| JP2023518430A5 (https=) |